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ABSTRACT
Introduction Hyperthyroidism is a common condition 
affecting up to 3% of the UK population. Treatment 
improves symptoms and reduces the risk of atrial 
fibrillation and stroke that contribute to increased 
mortality. The most common symptom is weight loss, 
which is reversed during treatment. However, the weight 
regain may be excessive, contributing to increased risk 
of obesity. Current treatment options include antithyroid 
drugs, radioiodine and thyroidectomy. Whether there are 
differences in either weight change or the long- term 
cardiometabolic risk between the three treatments is 
unclear.
Methods and analysis The study will establish the 
natural history of weight change in hyperthyroidism, 
investigate the risk of obesity and risks of cardiometabolic 
conditions and death relative to the treatment. The data 
on patients diagnosed with hyperthyroidism between 1 
January 1996 and 31 December 2015 will come from 
Clinical Practice Research Datalink linked to Hospital 
Episode Statistics and Office of National Statistics Death 
Registry. The weight changes will be modelled using a 
flexible joint modelling, accounting for mortality. Obesity 
prevalence in the general population will be sourced 
from Health Survey for England and compared with the 
post- treatment prevalence of obesity in patients with 
hyperthyroidism. The incidence and time- to- event of major 
adverse cardiovascular events, other cardiometabolic 
outcomes and mortality will be compared between the 
treatments using the inverse propensity weighting model. 
Incidence rate ratios of outcomes will be modelled 
with Poisson regression. Time to event will be analysed 
using Cox proportional hazards model. A competing 
risks approach will be adopted to estimate comparative 
incidences to allow for the impact of mortality.
Ethics and dissemination The study will bring 
new knowledge on the risk of developing obesity, 
cardiometabolic morbidity and mortality following 
treatment for hyperthyroidism to inform clinical 
practice and public health policies. The results will 
be disseminated via open- access peer- reviewed 
publications and directly to the patients and public groups 
(Independent Scientific Advisory Committee protocol 
approval #20_000185).
INTRODUCTION
Hyperthyroidism is a common condition 
affecting 3% of women and 0.3% of men 
in the UK.1 Common clinical features indi-
cating hyperthyroidism include weight loss, 
heat intolerance, tremor, palpitations and 
anxiety.2 Treatment is critical to minimise 
complications including atrial fibrillation and 
stroke that contribute to the observed 20% 
increase in mortality.3
There are three treatment options: anti-
thyroid drugs (ATDs), radioactive iodine 
(I- 131, radioiodine) or surgical, either as a 
total or hemithyroidectomy. ATDs are associ-
ated with a high rate of relapse (30%–70%),4 
while treatment with radioiodine or thyroid-
ectomy leads to the development of hypo-
thyroidism, requiring lifelong levothyroxine 
replacement, which is seen in 80% of patients 
administered radioiodine and up to 100% 
undergoing thyroidectomy. Guidance recom-
mends discussion of all three options with the 
patient.5 6 There is insufficient evidence to 
recommend one treatment over the others, 
although some studies indicate differences 
Strengths and limitations of this study
 ► Rich data from a large sample allowing for pre- 
exposure history and long follow- up, spanning 
across primary and secondary care.
 ► Contextualisation of post- treatment obesity prev-
alence by comparison with the general population 
adjusted for sex and age.
 ► A broad range of patient- relevant cardiometabolic 
outcomes will be evaluated.
 ► Large real- world observational study of treatment 
options not amenable to randomised clinical trials.
 ► The study’s main limitations are related to the intrin-
sic nature of the real- world data, such as the sec-
ondary use of data or the presence of missing data.
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in cardiac events and mortality between the treatment 
modalities.7 8
Weight gain following various treatments for hyper-
thyroidism has been described.9 10 Clinicians commonly 
assume that the observed weight gain is a simple regain of 
weight lost prior to the initiation of treatment. However, 
an analysis of 1373 patients with hyperthyroidism has 
demonstrated a higher prevalence of obesity at 3 years 
of follow- up when compared with the age- matched and 
sex- matched background population (37% vs 26% in 
men, p<0.001; 32% vs 26% in women, p<0.001).11 These 
findings suggest excess weight gain beyond patients’ 
premorbid weight (weight overshoot). Additionally, the 
study showed significant differences in final weight gain 
compared with baseline between those treated with ATDs 
(5.4 kg, 95% CI 4.8 to 6.0) and those who received radio-
iodine but did not develop hypothyroidism (5.1 kg, 95% 
CI 4.3 to 6.1) when compared with those treated with 
radioiodine who developed subsequent hypothyroidism 
(7.1 kg, 95% CI 6.6 to 7.7). The extent of weight change 
in patients treated with thyroidectomy was not evaluated.
Prior to diagnosis, the majority of patients with hyper-
thyroidism notice that they lose weight, often despite 
increased appetite, due to the regulatory effects of 
thyroid hormones on metabolism. As thyroid hormone 
levels normalise following treatment, weight change may 
be observed. While weight gain following treatment is 
common, it may become a major psychological stressor 
and can affect treatment compliance. Untreated hyper-
thyroidism may result in serious consequences, including 
thyroid storm, heart failure, embolic events, atrial fibril-
lation, osteoporosis, muscle weakness, neuropsychi-
atric symptoms and, rarely, cardiovascular collapse and 
death.12 Patients need to be appropriately counselled 
about the possibility of significant weight gain associated 
with the treatment of hyperthyroidism. However, there 
are currently insufficient data available about weight 
overshoot, cardiovascular risk and treatment modality 
selection to provide clear guidance to our patients. In our 
recent survey of British Thyroid Association members, 
of 35 clinicians who responded, only 23% usually discuss 
weight gain with patients treated for hyperthyroidism 
despite 70% of respondents feeling this was a significant 
clinical problem.
We recently surveyed doctors and dieticians and found 
that while there was agreement that weight gain following 
treatment for hyperthyroidism represents a medical 
problem, there is no consensus about the significance of 
or the approach to this anticipated weight gain. When 
surveyed, dieticians expressed concerns that they are not 
equipped to advise on dietary issues, given the switch from 
a highly catabolic state (weight loss state) in untreated 
hyperthyroidism to a situation of anticipated weight gain 
following treatment.
As previously shown, hyperthyroidism is associated with 
increased cardiovascular morbidity and mortality, which 
are not completely reversed by treatment.7 8 13 14 Among 
cardiovascular comorbidities, atrial fibrillation is the most 
common, occurring in 2%–20% of untreated patients,15 
and complications including heart failure and thrombo-
embolic events are observed in patients with hyperthy-
roidism. In a recent meta- analysis, an increased risk of 
atrial fibrillation with higher concentrations of thyroid 
hormones at presentation was confirmed.16 In a nation-
wide register study with a mean follow- up time of 10 years, 
an increased risk of all arrhythmias was found in patients 
undergoing treatment with radioiodine or thyroidec-
tomy when compared with controls with no thyroid 
dysfunction.8 Patients with subclinical hyperthyroid and 
hypothyroid dysfunctions were found to have increased 
risks of heart failure (HR=1.94, 95%CI 1.01 to 3.72 for 
thyroid- stimulating hormone (TSH) <0.10 mIU/L and 
HR=1.86, 95% CI 1.27 to 2.72 for TSH >10.0 mIU/L) in a 
pooled analysis of individual participant data using avail-
able prospective cohorts with thyroid function tests and 
subsequent follow- up of heart failure.17 In a large cohort 
of UK patients on levothyroxine replacement, mortality 
was increased in the lowest (<0.1) and highest TSH cate-
gories (>4.0) compared with 2.0–2.5 mIU/L, while risks 
of ischaemic heart disease and heart failure were found to 
increase at high concentrations of TSH (>10.0 mIU/L).18
There is insufficient evidence to systematically review 
the differences in health outcomes between the three 
different treatments. Due to limitations arising from the 
need to adhere to radiation protection and varied require-
ments of the procedures (a prolonged course of medica-
tion, one- off radioiodine tablet or surgical procedure), 
randomisation and blinding between all three modalities 
is often not possible, making randomised controlled trials 
nearly non- existent in this area of research.
At our recent patient engagement event, patients felt 
that there was insufficient information to help guide the 
choice of treatment. They were concerned about the risk 
of excessive weight gain and its long- term cardiometa-
bolic consequences and frustrated with the lack of infor-
mation, allowing them to prioritise one treatment over 
the other. There was also disappointment about the lack 
of support services addressing weight and diet across 
treatment for hyperthyroidism. Patients were particularly 
concerned about the perceived risk of weight gain associ-
ated with radioactive iodine and agreed that proper quan-
tification of weight gain and cardiovascular risks across 
the treatments would influence their therapy preferences 
and could inform anticipatory dietary modification.
Aims and objectives
The overall aim of this study was to investigate the risks 
of gaining weight and developing obesity, developing 
cardiometabolic conditions or death following treatment 
for hyperthyroidism and to compare these risks between 
the three treatment modalities.
Primary objective
The primary aim of this study was to assess the effect of type 
of treatment on weight changes during and after therapy 
for hyperthyroidism. The post- treatment prevalence of 
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obesity will also be evaluated and compared with that of 
the general population.
Secondary objectives
Further, the effect of treatment and weight status on 
the incidence of major adverse cardiovascular events 
(MACEs), other cardiometabolic outcomes and mortality 
following each treatment modality will be evaluated.
METHODS
This is a retrospective, longitudinal, observational study 
using routinely collected data. Data for the study will come 
from the Clinical Practice Research Datalink (CPRD), 
linked to Hospital Episode Statistics (HES) admissions 
and outpatient databases. The study is to be conducted 
between 1 February 2021 and 31 July 2022. The protocol 
was approved by the Independent Scientific Advisory 
Committee (ISAC #20_000185).
Data sources
CPRD collects and anonymises patient electronic health 
record data from a network of general practitioner (GP) 
practices across the UK.19 Although the records in the 
database cover all four UK countries, HES- linkable records 
are limited to those from England only. Two HES datasets 
will be used: HES outpatient and HES admitted patient 
care. Linkage to HES databases is required to obtain 
the data, which may be missing from the GP records on 
non- medical treatment for hyperthyroidism (radioactive 
iodine and thyroidectomy). Additionally, data on MACEs 
will also be sourced from HES, as such events are typically 
being treated in the hospital setting.
Linkage to social data is required to adjust the analysis 
for socioeconomic status, which is a known risk factor 
for obesity and increased mortality. This will be obtained 
as the Index of Multiple Deprivation (IMD). Linkage to 
Office of National Statistics data is required to get access 
to the date of death and cause of death. Prevalence of 
post- treatment obesity will be compared with the back-
ground population sourced from Health Survey for 
England, a yearly survey monitoring trends in the nation’s 
health and care.
Population
Adult patients (≥18 years) who were for the first time 
diagnosed with hyperthyroidism (the list of codes in 
online supplemental appendix) between 1 January 1996 
and 31 December 2015 will be eligible for inclusion. To 
minimise missed cases, the diagnosis will be additionally 
identified by a prescription of carbimazole or propylth-
iouracil, which are ATDs indicated only for treatment of 
hyperthyroidism. A minimum of 12 months of data must 
be available before the date of diagnosis and after the 
index date. CPRD records need to be classified as accept-
able research quality.
Exclusion criteria encompass ATD treatment of dura-
tion shorter than 6 months as the only treatment, that 
is, with no radioactive iodine or thyroidectomy followed. 
This is to avoid contamination by misdiagnosis or spon-
taneously resolving thyroiditis. Patients treated with 
both definitive treatment methods, that is, radioiodine 
and thyroidectomy, will also be excluded. However, ATD 
treatment followed by either radioiodine or thyroidec-
tomy (one of the definitive treatments) is considered 
a pretreatment and does not constitute an exclusion 
criterion.
Exposure
The exposure in the study is the treatment for hyper-
thyroidism. The study patients will be divided into three 
groups based on the treatment administered: (1) radioio-
dine: the allocation to this treatment arm will be assigned 
based on the Read code or OPCS- 4 code of the treatment 
procedure for radioiodine; (2) thyroidectomy: the alloca-
tion to this treatment arm will be assigned based on the 
Read code or OPCS- 4 code of the surgical procedure; 
(3) medical treatment arm will be identified based on 
the absence of radioiodine treatment code and thyroid-
ectomy code in the presence of ATD treatment (based 
on the Read code or British National Formulary (BNF) 
code) longer than 6 months.
We anticipate good quality of ATD prescription and 
thyroidectomy. However, radioiodine, typically adminis-
tered in outpatients, may be missed in a substantially high 
proportion of patients. Since ATD treatment does not 
incur permanent hypothyroidism, the long- term prescrip-
tion of levothyroxine for hypothyroidism following treat-
ment with ATD alone, that is, without any definitive 
procedures, will be considered as a proxy for radioiodine 
administration.
Outcomes
The primary outcome is weight change (in kilogram) 
during and following the treatment for hyperthyroidism, 
as well as prevalence of obesity following the treatment. 
The secondary outcomes include cardiometabolic events 
and mortality as presented in table 1.
Table 1 Secondary outcomes and their data sources
Secondary outcome Source
MACE (cardiovascular death, nonfatal 
myocardial infarction or non- fatal stroke)
HES
Type 2 diabetes mellitus CPRD
Congestive heart failure HES
Ischaemic heart disease HES
Stroke and transient ischaemic attack HES
Cardiovascular mortality ONS
All- cause mortality ONS
CPRD, Clinical Practice Research Database; HES, Health Episode 
Statistics; MACE, major adverse cardiovascular event; ONS, Office 
for National Statistics.
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Confounding
Based on the literature and clinical experience, we 
identified a number of confounders affecting both the 
exposure and the outcomes of our study. The modelled 
outcomes will be adjusted for baseline data (sex, age, 
IMD quartiles, smoking status and comorbidities) and 
time- varying covariates (thyroid function, cumulative 
time on the medical treatment, time since diagnosis, 
levothyroxine replacement, pregnancy and diagnosis of 
cancer). Table 2 presents the details of how covariates 
are defined and handled. Figure 1 depicts the directed 
acyclic graphs representing the relationship between the 
covariates. We will explore the relationships between the 
potential confounders and both exposures and outcomes 
independently in order to establish their potential role in 
this particular dataset.
Index date and follow-up
The index date in the cohort is the date of initiation of 
treatment for hyperthyroidism, which defines the treat-
ment group (either ATD, radioiodine or thyroidectomy). 
There is a requirement of at least 12 months’ data avail-
able prior to the index date.
The natural history of weight changes will be modelled 
preindex and postindex date. While the follow- up for 
the analysis of outcomes will start at the index date, a 
minimum of 12- month follow- up is required for the 
inclusion.
Data analysis
Natural history of weight changes
Descriptive statistics will provide summaries about the 
sample and weight as the outcome measure.
The natural history of weight changes will be modelled 
longitudinally. The model will estimate the weight (kilo-
gram) over three stages: premorbid, duration of treat-
ment and post- treatment. Premorbid weight is defined as 
body weight recorded at least 3 months before diagnosis 
or treatment initiation (whichever comes first). The treat-
ment phase will start from the time of diagnosis or the first 
prescribed dose or procedure and will last until 3 months 
after the last recorded date of treatment. Any weight 
recoded thereafter will be considered as post- treatment.
Table 2 Definitions of study covariates
Variable Definition
Aetiology of hyperthyroidism Identified based on Read codes and categorised in (1) Graves’ disease, (2) toxic nodular 
goitre and (3) undefined. The undefined category will consist of unspecified diagnosis 
and missing aetiology data.
Age Age at index date
Baseline fT4 The highest measurement between 3 months prior to diagnosis and the index date
BMI Normal (or underweight) <25 kg/m2, overweight 25–30 kg/m2 and obese ≥30 kg/m2; 
additionally, BMI status will be deduced from the Read code
Cancer diagnosis Switch- type binary variable assuming lifelong status of cancer comorbidity
Frequency of GP visits Time- varying variable of number of GP visits in a unit of time
IMD IMD will be stratified into quintiles.
Levothyroxine (LT4) replacement Switch- type binary variable assuming lifelong LT4 administration following development 
of hypothyroidism in radioiodine and thyroidectomy treatment groups
Pregnancy Time- varying binary variable recording pregnancy
Pretreatment ATD Cumulative time on ATD between diagnosis and the index date
Sex Binary variable
Smoking status As recorded at the index date, last observation carried forward if not available at the 
index date
TSH Serial TSH, log- transformed for the analysis
Time since diagnosis Time- varying variable measuring cumulative time since diagnosis
ATD, antithyroid drug; BMI, body mass index; GP, general practitioner; IMD, Index of Multiple Deprivation; TSH, thyroid- stimulating hormone.
Figure 1 Directed acyclic graph illustrating confounding 
in the study. The wide dark arrow indicates the relationship 
of interest. ATD, antithyroid drugs; IMD, Index of Multiple 
Deprivation; TFT, thyroid function test.
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Only patients having at least one weight record (quan-
titative or qualitative) in each of the three phases of the 
condition (premorbid, treatment and post- treatment) 
will be included in the natural history of weight analysis. 
The extent of missing data will be reported. As with any 
real- world data, we anticipate a relatively high propor-
tion of intermittent missing weight data. This missing-
ness can be assumed to be missing at random conditional 
on other covariates.20 Hence, the missing values will be 
imputed using the multiple imputation by chained equa-
tions (MACE).21 To improve precision of the imputation, 
the existing qualitative information from Read codes 
stating the direction of change (eg, ‘weight increasing 
(1622.00)’) or body mass index (BMI) status (eg, ‘over-
weight (22AA.00)’) together with other demographic 
and clinical covariate data will be entered into the impu-
tation regression model.
Additionally, in order to allow for the fact that patients 
may die, and their weight trajectories will be subject to 
informative dropout due to death, we will model weight 
changes using a flexible joint modelling approach.22 
Effectively, the analysis of weight history will combine 
three techniques: (1) complete- case analysis (including 
only patients with at least one, either quantitative or 
qualitative, weight status code in each of the phases); (2) 
imputation of weight where qualitative codes are present; 
and (3) joint modelling to incorporate the informative 
missingness due to death. To check the sensitivity of the 
correctly specified imputation model, a fully Bayesian 
approach that jointly imputes missing values and esti-
mates the parameters of the longitudinal model will also 
be conducted.23–25 Weight in all three treatment groups 
will be modelled simultaneously; the ATD group will 
be used as the reference group. Any marginal pairwise 
comparisons will be corrected for multiple testing by 
applying Bonferroni correction.
Further, the sensitivity to death and to missed treat-
ment coding will be checked. During our meetings with 
the patients, we were informed that weight changes are 
important but are not of the utmost priority. In the face of 
death or any serious illness, weight maintenance loses its 
importance. Hence, our interest in weight changes in an 
immortal cohort, and thus, we would like to model weight 
in patients in such health that allows them to survive to 
the end of the study. Patients who died during the study 
will be excluded.
Prevalence of obesity
Post- treatment obesity in patients will be defined 
as ≥30 kg/m2, in line with the WHO definition,26 or iden-
tified from the Read codes when quantitative values are 
not available. The prevalence of obesity will be assessed in 
the entire cohort and stratified by the treatment group.
The post- treatment BMI will be compared with those in 
the background population (Health Survey for England). 
Two measures of effect will be investigated: (1) difference 
in overall BMI (kg/m2) and (2) difference in proportions 
of obesity. The effects will be tested with linear regression 
and logistic regression, respectively, in reference to the 
background population. The analyses will be adjusted for 
age and stratified by sex. Only complete case analysis will 
be conducted.
Cardiometabolic risks and mortality
The descriptive analysis of primary and secondary 
outcomes will provide useful summaries about the sample 
and the outcome measures. Besides the unadjusted 
descriptive statistics, such as the incidence rate of each 
outcome, simple graphics analysis will be provided.
Causal inference in the analysis of cardiometabolic 
outcomes and mortality will be undertaken using inverse 
propensity weighting (IPW). This method was empirically 
shown to be superior to other propensity score- based 
approaches in analysis of multiple treatments with a binary 
outcome.27 The propensity- score matching, even though 
well valuated in two- arm treatment, in multiple treat-
ments might introduce bias; the IPW is more efficient in 
such scenario. Additionally, IPW method is more flexible 
and requires weaker unconfoundedness assumption.28
Generalised propensity weights with treatment category 
as dependent variable will be calculated in the multinom-
inal logistic model.29 The model will be developed using 
the following covariates: age at the index date, sex, base-
line serum fT4, aetiology of hyperthyroidism, smoking 
status, IMD, cumulative time on ATD between diagnosis 
and the index date, time since diagnosis and BMI status.
Variables related to treatment, as an outcome, at 
p<0.10 will be selected for inclusion in the multiple 
propensity weights.30 To identify these variables, we will 
conduct several regression analyses with the treatment as 
a dependent and each potential confounder as an inde-
pendent variable. Furthermore, it will be investigated 
whether adding interaction terms or higher- order terms 
for continuous variables will improve the balance of the 
model. The Hausman test will be used to check the inde-
pendence of irrelevant alternatives assumption, which is 
the main assumption of multinomial regression analysis.30 
If this assumption is not met, multinomial probit analysis 
will be used instead.
The estimation of propensity weights will be conducted 
by the method proposed by McCaffrey et al.31 32 The appro-
priateness of IPW analysis will be assessed by checking the 
overlap (positivity assumption). According to the posi-
tivity assumption, each patient should have a non- zero 
probability of being indicated to each treatment category. 
Lack of overlap in the distribution of observed pretreat-
ment characteristics between groups receiving different 
treatment indicates the positivity assumption is violated. 
This overlap will be checked visually. If poor overlap 
is identified, we will use Rubin’s trimming method,33 
allowing discarding non- overlapping cases.
Further, pairwise balance in the distribution of all 
included variables between the three treatment groups 
will be tested with linear regression for continuous vari-
ables, logistic regression for binary and multinomial 
logistic regression for nominal variables. The analysis 
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will be done without and with adjustments. The propen-
sity weights will be considered balanced if there are no 
statistically significant (p<0.05) differences between the 
likelihood of receiving a different type of treatment. If 
imbalances remain after weighting, a doubly robust esti-
mation approach will be applied32; that is, the imbalanced 
variables will be added to the model.
While IPW will adjust for confounding at baseline, 
other time- varying adjustments will be applied to correct 
for the events between the baseline and the outcome. The 
proposed covariates are treatment with levothyroxine for 
developed hypothyroidism, log TSH levels and informa-
tive observations of number of GP visits in a unit of time.
Incidence rate ratios of outcomes will be calculated 
with Poisson regression and modelled adjusting for time- 
varying covariates as listed further. Time- to- event anal-
ysis with adjustments will be modelled. The appropriate 
model will be applied, depending on the proportional 
hazard assumption’s results: if the assumption holds—
Cox proportional hazard regression will be used; if it 
is violated, alternative techniques such as time- varying 
measures in extended Cox models will be applied.
Proposed time- varying adjustments for both analyses 
will include postindex date data, that is, treatment with 
levothyroxine for developed hypothyroidism, logTSH 
levels and informative observations of number of GP 
visits in a unit of time. To allow for the fact that patients 
may die, a competing risks approach will be adopted for 
estimating comparative incidences for non- fatal events to 
allow for the impact of mortality as a competing risk.22
Sensitivity to missed radioiodine record
Whenever ATD patients develop permanent hypothy-
roidism, a radioiodine treatment will be assumed, as 
explained in the Exposure section. All analyses will be 
repeated to check sensitivity to this assumption, excluding 
patients in the ATD group who developed hypothyroidism 
following medical treatment being the only antithyroid 
treatment on record.
Patient and public involvement
Our patients with hyperthyroidism have been pivotal in 
formulating the research questions and informing the 
study design. The study idea originated from listening 
to patients and their concerns. As part of the consulta-
tion process, we held a meeting, advertised locally and 
nationally via the British Thyroid Foundation (BTF), with 
patients who had either previously been treated or were 
currently being treated for hyperthyroidism. During an 
open discussion, key themes were identified as important 
to patients across the treatment course of hyperthyroidism. 
At diagnosis, patients often reported that there was insuf-
ficient information to determine which treatment choice 
would be best for them, particularly regarding long- term 
treatment consequences; hence, a major driver of the 
study design is the examination of long- term cardiomet-
abolic outcomes. The comment that “radioactive iodine 
will make me fat” was repeatedly mentioned in the group 
discussion. We were already interested in the potential 
issue of weight gain beyond premorbid weight, and this 
is something we will be investigating in this project. The 
main themes reported were that in addition to insufficient 
information to make a clear, informed treatment choice, 
patients did not feel that they were suitably counselled 
about weight regain nor that there was a mechanism in 
place to predict or modulate this potential effect. The 
insufficiency of information on the treatment choices and 
their long- term consequences was further confirmed in 
a BTF survey involving 353 patients. Among responders 
who received definitive treatment (n=167) who therefore 
had knowledge of postdefinitive treatment procedure 
effects, a third would have not decided to proceed with 
their choice of treatment.
To continue guidance by patients, we have formed a 
patient group, which was engaged at the design stage and 
will continue to advise us during the project. Additionally, 
a BTF representative (JP) joined our team as a coappli-
cant to represent patients’ voices regularly throughout 
the research process. As the study progresses, the patient 
group and the patients’ representative will be involved 
in rationalising the design if any challenges are encoun-
tered, in discussing the implications and relevance of 
the emerging results, and in finalising the key messages 
of the study to facilitate patient- centred dissemination. 
We will involve our patient partners in the dissemination 
of the results and the development of future avenues of 
research.
Additional guidance comes from the GP advisory group 
(SJF and PS), who has shared its experience and expertise 
from the front- end of data collection. This was especially 
important while establishing the feasibility of model-
ling and interpreting the weight changes based on the 
already recorded weight entries. The GP advice will be 
further used in the interpretation of results, dissemina-
tion process and the planning of further initiatives.
ETHICS AND DISSEMINATION
The study protocol has been approved by the ISAC in 
March 2021 (#20_000185). ISAC is a non- statutory expert 
advisory body established in 2006 by the Secretary of 
State for Health to provide scientific advice on research 
requests to access data provided by CPRD.
The primary aim was to inform clinical practice within 
the NHS and to provide evidence for future research in 
managing long- term consequences of hyperthyroidism 
and its treatment. The dissemination plan targets audi-
ences at various levels: clinical and academic as well as 
patients and public. To address the needs of the former, 
we are planning to share the findings at the scientific 
endocrinology meetings and to publish them in leading 
open- access peer- reviewed academic journals. The BTF, a 
national community of patients with thyroid conditions 
in the UK, will play a key role in disseminating the results 
of the study to the public, patients and their families and 
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carers. The BTF will share results via traditional and social 
media channels.
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APPENDIX: Medical codes used for data search  
 
Table 1: Read codes for diagnosis of hyperthyroidism  
Read code   Description  
C02..00   Thyrotoxicosis  
C02..11   Hyperthyroidism  
C02..12   Toxic goitre  
C020.00   Toxic diffuse goitre  
C020.11   Basedow's disease  
C020.12   Graves' disease  
C020000   Toxic diffuse goitre with no crisis  
C020100   Toxic diffuse goitre with crisis  
C020200   Thyroid-associated dermopathy  
C020z00   Toxic diffuse goitre NOS  
C021.00  Toxic uninodular goitre  
C021000   Toxic uninodular goitre with no crisis  
C021100  Toxic uninodular goitre with crisis  
C021z00  Toxic uninodular goitre NOS  
C022.00  Toxic multinodular goitre  
C022000  Toxic multinodular goitre with no crisis  
C022100  Toxic multinodular goitre with crisis  
C022z00  Toxic multinodular goitre NOS  
C023.00  Toxic nodular goitre unspecified  
C023000  Toxic nodular goitre unspecified with no crisis  
C023100  Toxic nodular goitre unspecified with crisis  
C023z00  Toxic nodular goitre NOS  
C024.00  Thyrotoxicosis from ectopic thyroid nodule  
C024000  Thyrotoxicosis from ectopic thyroid nodule with no crisis  
C024100  Thyrotoxicosis from ectopic thyroid nodule with crisis  
C024z00  Thyrotoxicosis from ectopic thyroid nodule NOS  
C02y.00  Thyrotoxicosis of other specified origin  
C02y.11  Factitia thyrotoxicosis  
C02y000  Thyrotoxicosis of other specified origin with no crisis  
C02y100  Thyrotoxicosis of other specified origin with crisis  
C02y200  Thyrotoxicosis factitia  
C02y300  Thyroid crisis  
C02yz00  Thyrotoxicosis of other specified origin NOS  
C02z.00  Thyrotoxicosis without mention of goitre or other cause  
C02z000  Thyrotoxicosis without mention of goitre or cause no crisis  
C02z100  Thyrotoxicosis without mention of goitre, cause with crisis  
C02zz00  Thyrotoxicosis NOS  
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Table 2: Codes for the treatment group allocation  
 
Treatment group allocation  Coding system 








Propylthiouracil    06.02.02.00   
  
Radioiodine:  









I131 radiotherapy  5A16.11      
Iodine 131 radiotherapy  5A16.12      
  
Thyroidectomy:  









Thyroidectomy operations  7110.00      
Excision of thyroid gland operations  7110.11      
Total thyroidectomy  7110000    B08.1  
Subtotal thyroidectomy  7110100    B08.2  
Bilateral subtotal thyroidectomy  7110111    B08.2  
Hemithyroidectomy  7110200    B08.3  
Lobectomy of thyroid gland NEC  7110300    B08.4  
Isthmectomy of thyroid gland  7110400    B08.5  
Partial thyroidectomy NEC  7110500    B08.6  
Thyroidectomy NEC  7110600    B08.6  
Other specified thyroidectomy  7110y00    B08.8  
Thyroidectomy NOS  7110z00   B08.9  
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Table 3: Outcomes codes 
 
Outcome  Coding system 
 ICD-10  Read codes 
obesity   
  
22K5.00, 66C..00, 66CZ.00, C38..00,  
C380.00, C380.00, C380000, C380100,  
C380200, C380300, C380400, C380500,  
C38y011, C38z.00, C38z000  
nonfatal myocardial infarction 
(composite of MACE)  I21-I22  n/a  
nonfatal stroke   
(composite of MACE)  I64  n/a  
congestive heart failure  I50  n/a  
ischaemic heart disease  I20-I25  n/a  
stroke and transient ischaemic 
attack (TIA)  I60-I69  n/a  
type 2 diabetes mellitus  E11  C109*  
  
MACE: major adverse cardiovascular event; TIA: transient ischemic attack 
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